Viability of GDP in Lymphoma

This study set out to determine that patients with relapsed or refractory aggressive lymphoma would receive the same benefit from gemcitabine-based therapy as from standard therapy with DHAP (dexamethasone, cytarabine, cisplatin) prior to autologous stem-cell transplantation. 

Patients (n = 619) with relapsed or refractory lymphoma were randomly assigned to receive either gemcitabine, dexamethasone and cisplatin (GDP) or DHAP. For more information, click here.



Global Database

Information by country, region and/or subtype on treatments, clinical trials and incidence/mortality rates.

Resource Library

Over 2,000 pieces of information on lymphoma diagnosis, treatment, research, support and lifestyle.

logo europe


Have you ever attended a meeting with a lymphoma support group?




The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or
require more detailed information on the best course of treatment for you.

Our website does not host any form of advertisement. Last updated: 03/27/18. Copyright © 2018 Lymphoma Coalition. All rights reserved.